Lyell Immunopharma CEO to discuss cancer cell therapies at H.C. Wainwright conference

Lyell Immunopharma, Inc. (LYEL) will take part in the H.C. Wainwright 4th Annual BioConnect Investor Conference later this month. CEO Lynn Seely is scheduled for a fireside chat on May 19, 2026, at 11:00 AM EDT. The session will be moderated by senior biotech analyst Mitchell Kapoor from H.C. Wainwright & Co, LLC. Lyell specialises in next-generation cell therapies for cancer treatment. Its pipeline includes two lead clinical programmes. The first, ronde-cel, targets large B-cell lymphoma—a $3 billion market for CD19-directed CAR T-cell therapies. This dual-targeted therapy focuses on both CD19 and CD20 markers.

The company’s second programme addresses metastatic colorectal cancer. Like ronde-cel, it represents a novel CAR therapy designed for a significant patient population. Kapoor, who covers Lyell for H.C. Wainwright, will guide the discussion. The fireside chat offers investors a chance to hear directly from Seely about the company’s progress and strategy.

The event provides a platform for Lyell to highlight its clinical advancements. Investors and analysts will gain insights into the company’s approach to treating both blood cancers and solid tumours. The session is set to run for one hour during the conference.